GENFIT Files 2024 Universal Registration Document
Lille, France - GENFIT (Nasdaq and Euronext: GNFT), a pioneering biopharmaceutical firm dedicated to the welfare of patients suffering from rare and life-threatening liver conditions, has achieved a significant milestone by filing its 2024 Universal Registration Document alongside its Annual Report on Form 20-F with relevant financial authorities.
Availability of Annual Reports
Both the Universal Registration Document and the Annual Report on Form 20-F, detailing fiscal year-end information as of December 31, 2024, are made available to the public. Interested parties can access these documents for free according to regulations. They are readily downloadable from GENFIT's official website, enhancing transparency and accessibility for stockholders and stakeholders alike.
Comprehensive Overview of Key Documents
Within these annual filings, GENFIT has included a variety of essential reports:
- The annual financial report that outlines the company's financial performance.
- An annual management report detailing strategic directions and business operations.
- A comprehensive report from the Board of Directors regarding corporate governance practices.
- Reports from Statutory Auditors concerning the annual and consolidated financial statements, including related-party agreements.
- A breakdown of statutory auditing fees.
About GENFIT
At the forefront of biopharmaceutical innovation, GENFIT seeks to revolutionize treatments for acute and chronic liver diseases, where patient needs are significantly unmet. Over two decades of research and development have solidified GENFIT’s reputation as a leader in this critical sector. Currently, the company is focused on enhancing its diverse R&D portfolio, which includes programs at various development stages aimed at treating Acute-on-Chronic Liver Failure (ACLF).
Ongoing Development Programs
GENFIT’s ACLF initiative features five promising assets: VS-01, G1090N, SRT-015, CLM-022, and VS-02-HE. These assets employ a variety of mechanisms and administration routes, demonstrating GENFIT’s innovative approach to tackling complex medical issues. Moreover, the company remains committed to addressing additional severe conditions, such as cholangiocarcinoma, urea cycle disorders, and organic acidemias.
Market Presence and Achievements
Headquartered in Lille, France, with offices in Paris, Zurich, and Cambridge, MA, GENFIT operates on both the Nasdaq Global Select Market and Euronext regulated market, ensuring its presence is acknowledged on multiple fronts. The company's growth was notably highlighted in 2021 when Ipsen acquired an 8% stake, reinforcing confidence in GENFIT's trajectory.
Remarkable Advances in Drug Development
GENFIT's commitment to excellence is reflected in the accelerated approval of their innovative medication, Iqirvo (elafibranor), by FDA, EMA, and MHRA, illustrating the company’s capabilities in navigating the complexities of drug validation and commercialization.
Contact Information
For further inquiries regarding investor relations, individuals may reach out via telephone at +33 3 20 16 40 00 or contact the team through email.
GENFIT | Investors
Tel : + 33 3 20 16 40 00 | investors@genfit.com
GENFIT | Press Relations
Stephanie BOYER | Tel : + 33 3 20 16 40 00 | stephanie.boyer@genfit.com
Frequently Asked Questions
What is the purpose of the 2024 Universal Registration Document?
The Universal Registration Document provides essential financial and management information to stakeholders and regulatory authorities, ensuring transparency.
Where can I access GENFIT's annual reports?
The annual reports can be accessed and downloaded for free on GENFIT's official website.
What diseases does GENFIT primarily focus on?
GENFIT primarily focuses on rare and life-threatening liver diseases, particularly Acute-on-Chronic Liver Failure.
How has GENFIT expanded its R&D portfolio?
GENFIT has diversified its R&D portfolio by developing multiple treatment programs targeting liver diseases and related conditions.
What significant partnerships has GENFIT established?
In 2021, Ipsen became a major shareholder by acquiring an 8% stake, illustrating strong support for GENFIT's growth potential.
